Jeremy Bender

Meet Jeremy Bender

Under Jeremy’s leadership, Day One Biopharmaceuticals obtained its first FDA approval in April 2024. Ojemda (tovorafenib) is a targeted therapy for children living with pediatric low-grade glioma. Jeremy is committed to closing the innovation gap between adult and pediatric therapies by addressing the urgent unmet needs of people of all ages with cancer. His work at Day One aims to fundamentally shape the way pediatric diseases are studied and treated. 

“Listening to patients and their families and caregivers about their experiences to understand how new medicines can make patients’ lives better. Hearing that a new medicine I’ve worked on has helped a patient fills me with gratitude and joy, and carries me through the inevitable challenges and setbacks that all of us in drug development face.”